Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with “no serious adverse events”, according to research published in The Lancet, but experts said the trials were too small to prove safety and effectiveness.

Russia announced last month that its vaccine, named “Sputnik V” after the Soviet-era satellite that was the first launched into space in 1957, had already received approval.

This raised concerns among Western scientists over a lack of safety data, with some warning that moving too quickly on a vaccine could be dangerous. 

Aljazeera

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.